YMAB - Y-mAbs Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
38.18
+0.52 (+1.38%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Engulfing Line (Bearish)

Engulfing Line (Bearish)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close37.66
Open37.69
Bid36.40 x 800
Ask38.41 x 800
Day's Range36.68 - 39.24
52 Week Range14.16 - 40.88
Volume188,109
Avg. Volume267,106
Market Cap1.518B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.50
Earnings DateMay 08, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Should You Own This Sleeper Biotech Stock?
    Motley Fool

    Should You Own This Sleeper Biotech Stock?

    Several have returned to the capital markets to load up on cash to fund ongoing research and development (R&D) efforts. Among this crowd, Y-mAbs Therapeutics (NASDAQ: YMAB) continues to execute as its stock price climbs. Y-mAbs's lead drug candidate, naxitamab, aims to be the first choice for maintenance therapy for patients with relapsed or refractory neuroblastoma.

  • GlobeNewswire

    Y-mAbs Announces Data to be Presented at 2020 ASCO Annual Meeting

    NEW YORK, May 13, 2020 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • Investing.com

    H.C. Wainwright Sticks to Their Buy Rating for Y-Mabs Therapeutics Inc

    H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Y-Mabs Therapeutics (NASDAQ:YMAB) Inc on Monday, setting a price target of $52, which is approximately 30.52% above the present share price of $39.84.

  • YmAbs Therapeutics, Inc. (YMAB) Q1 2020 Earnings Call Transcript
    Motley Fool

    YmAbs Therapeutics, Inc. (YMAB) Q1 2020 Earnings Call Transcript

    In March, as Thomas just mentioned, we submitted the final portion of our rolling BLA for naxitamab in relapsed/refractory neuroblastoma, and we are now awaiting the potential PDUFA date from the FDA. The BLA is for the treatment of patients with relapsed/refractory high-risk neuroblastoma in bone and/or bone marrow.

  • GlobeNewswire

    Y-mAbs Announces First Quarter 2020 Financial Results and Recent Corporate Developments

    NEW YORK, May 07, 2020 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • Was The Smart Money Right About Y-mAbs Therapeutics, Inc. (YMAB)?
    Insider Monkey

    Was The Smart Money Right About Y-mAbs Therapeutics, Inc. (YMAB)?

    Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

  • GlobeNewswire

    UPDATE - Y-mAbs to Announce First Quarter 2020 Financial and Operating Results on May 7, 2020

    NEW YORK, April 30, 2020 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the first quarter.

  • GlobeNewswire

    Y-mAbs to Announce 2019 Financial and Operating Results on May 7, 2020

    NEW YORK, April 30, 2020 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the first quarter.

  • We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
    Simply Wall St.

    We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Y-mAbs Announces Appointment of Laura J. Hamill to its Board of Directors

    Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the Board of Directors (the “Board”) nominates healthcare executive Laura J. Hamill to be elected as a Class II director at the Company’s 2020 annual meeting of stockholders (the “Annual Meeting”). Laura will add significant commercial experience to our board, which will be of great value to our plans to augment our commercial organization and bring our product candidates to patients,” said Thomas Gad, Founder, Chairman, President, Head of Business Development and Strategy of Y-mAbs.

  • GlobeNewswire

    Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology – a Novel Radioimmunotherapy Platform

    Unbound constructs predictably disassemble into smaller antibody fragments and are excreted through the kidneys within hours after administration. In a second infusion, a radioactive payload binds to the antibody constructs to radiate the tumor.

  • GlobeNewswire

    Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Company has completed the submission of its Biologics License Application (“BLA”) under the FDA’s Rolling Review process for naxitamab after market close on March 31, 2020. Naxitamab is an investigational, monoclonal antibody that targets GD2. The submission is based on the safety and efficacy results of the pivotal Phase 2 studies 201 and 12-230, which the Company expects to present at a venue later this year.

  • GlobeNewswire

    Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments

    NEW YORK, March 12, 2020 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • ACCESSWIRE

    Y-mAbs Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at ...

  • GlobeNewswire

    Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020

    NEW YORK, March 05, 2020 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its 2019 financial and operating results on.

  • Benzinga

    The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate ...

  • GlobeNewswire

    Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has completed a positive Type B Pre-Biologics License Application (“Pre-BLA”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential pathway for FDA approval of omburtamab for the treatment of patients with CNS/leptomeningeal metastases from neuroblastoma. At the pre-BLA meeting, the Company reached alignment with the FDA on an Accelerated Approval Pathway for omburtamab along with a rolling BLA submission.

  • GlobeNewswire

    Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 07, 2020 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB), a late-stage clinical biopharmaceutical company focused on the development and.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCI

    Benzinga Pro's Stocks To Watch For Tuesday Tesla (TSLA) - Shares moved over the controversial "funding secured" $420 level which Elon Musk famously tweeted about in the summer of 2018. The intraday ...

  • Is Y-mAbs Therapeutics, Inc. (YMAB) A Good Stock To Buy?
    Insider Monkey

    Is Y-mAbs Therapeutics, Inc. (YMAB) A Good Stock To Buy?

    After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]

  • GlobeNewswire

    Y-mAbs’ GD2-GD3 Vaccine Granted Rare Pediatric Disease Designation

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based and immunotherapeutic products for the treatment of cancer, today announced that its GD2-GD3 Vaccine has been granted a Rare Pediatric Disease Designation (“RPDD”) by the FDA for  the treatment of neuroblastoma. The GD2-GD3 Vaccine was originally developed by researchers at Memorial Sloan Kettering (“MSK”), and licensed to MabVax Therapeutics Holdings, Inc. (“MabVax”), which sublicensed the compound for the treatment of neuroblastoma to Y-mAbs in 2018.

  • GlobeNewswire

    Y-mAbs Announces Positive Naxitamab Frontline Data 

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that positive frontline data for naxitamab will be presented at the Company’s R&D event, which takes place in New York City today at 12 p.m. Eastern. Key opinion leaders, including Dr. Shakeel Modak, M.D., MRCP and Dr. Kim Kramer, M.D., both from Memorial Sloan Kettering Cancer Center (“MSK”) and Dr. Jaume Mora, M.D., Ph.D. from SJD Barcelona Children's Hospital, will discuss the current treatment landscape and unmet medical needs for high-risk neuroblastoma and other solid tumors.

  • GlobeNewswire

    Y-mAbs and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for Omburtamab

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the European Medicines Agency (“EMA”) has agreed to the Company’s proposed Pediatric Investigation Plan (“PIP”) for omburtamab. The decision was made on the basis of a positive opinion from EMA’s Pediatric Committee (“PDCO”).

  • GlobeNewswire

    Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11

    NEW YORK, Dec. 05, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Y-mAbs Initiates Rolling Submission of Biologics License Application to U.S. FDA for Naxitamab for Treatment of Neuroblastoma

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) the first portions of its Biologics License Application (“BLA”) for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma under the FDA’s Rolling Review process. In August 2018, naxitamab, which is an anti-GD2 monoclonal antibody, received Breakthrough Therapy Designation by the FDA, which facilitates frequent interactions with the FDA review team.